Adderall Explained

Verifiedrevid:578643702
Drug Name:Amphetamine/dextroamphetamine
salt mixture (1:1)
Type:combo
Alt2:a 3d image of the dextroamphetamine compound found in Adderall
Component1:amphetamine aspartate monohydrate
Class1:25% – stimulant
Component2:amphetamine sulfate
Class2:25% – stimulant
Component3:dextroamphetamine saccharate
Class3:25% – stimulant
Component4:dextroamphetamine sulfate
Class4:25% – stimulant
Tradename:Adderall, Adderall XR, Mydayis
Dailymedid:Adderall
Legal Au:S8
Legal Ca:Schedule I
Legal De:Anlage III
Legal Nz:Class B
Legal Uk:Class B
Legal Us:Schedule II
Legal Un:Psychotropic Schedule II
Dependency Liability:Moderate[1] [2] – high[3] [4]
Routes Of Administration:By mouth, insufflation, rectal, sublingual
Bioavailability:Oral: ~90%
Atc Prefix:N06
Atc Suffix:BA02
Class: stimulant
Cas Number:300-62-9
Pubchem:3007
Iuphar Ligand:4804
Drugbank:DB00182
Chemspiderid:13852819
Unii:CK833KGX7E
Kegg:D11624
Chebi:2679
Chembl:405
Synonyms:Mixed amphetamine salts; MAS

Adderall and Mydayis[5] are trade names for a combination drug containing four salts of amphetamine. The mixture is composed of equal parts racemic amphetamine and dextroamphetamine, which produces a (3:1) ratio between dextroamphetamine and levoamphetamine, the two enantiomers of amphetamine.[6] Both enantiomers are stimulants, but differ enough to give Adderall an effects profile distinct from those of racemic amphetamine or dextroamphetamine,[7] [8] which are marketed as Evekeo and Dexedrine/Zenzedi, respectively.[9] [10] Adderall is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used illicitly as an athletic performance enhancer, cognitive enhancer, appetite suppressant, and recreationally as a euphoriant. It is a central nervous system (CNS) stimulant of the phenethylamine class.

At therapeutic doses, Adderall causes emotional and cognitive effects such as euphoria, change in sex drive, increased wakefulness, and improved cognitive control. At these doses, it induces physical effects such as a faster reaction time, fatigue resistance, and increased muscle strength. In contrast, much larger doses of Adderall can impair cognitive control, cause rapid muscle breakdown, provoke panic attacks, or induce a psychosis (e.g., paranoia, delusions, hallucinations). The side effects vary widely among individuals but most commonly include insomnia, dry mouth, loss of appetite and weight loss. The risk of developing an addiction or dependence is insignificant when Adderall is used as prescribed and at fairly low daily doses, such as those used for treating ADHD. However, the routine use of Adderall in larger and daily doses poses a significant risk of addiction or dependence due to the pronounced reinforcing effects that are present at high doses. Recreational doses of Adderall are generally much larger than prescribed therapeutic doses and also carry a far greater risk of serious adverse effects.

The two amphetamine enantiomers that compose Adderall, such as Adderall tablets/capsules (levoamphetamine and dextroamphetamine), alleviate the symptoms of ADHD and narcolepsy by increasing the activity of the neurotransmitters norepinephrine and dopamine in the brain, which results in part from their interactions with human trace amine-associated receptor 1 (hTAAR1) and vesicular monoamine transporter 2 (VMAT2) in neurons. Dextroamphetamine is a more potent Central nervous system stimulant than levoamphetamine, but levoamphetamine has slightly stronger cardiovascular and peripheral effects and a longer elimination half-life than dextroamphetamine. The levoamphetamine component of Adderall has been reported to improve the treatment response in some individuals relative to dextroamphetamine alone. The active ingredient in Adderall, amphetamine, shares many chemical and pharmacological properties with the human trace amines, particularly phenethylamine and, the latter of which is a positional isomer of amphetamine. In 2021 Adderall was the seventeenth most commonly prescribed medication in the United States, with more than 30million prescriptions.[11] [12]

Uses

Medical

Adderall is commonly used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy (a sleep disorder).[13] [14]

Available forms

Adderall is available as immediate-release (IR) tablets and extended-release (XR) capsules. Mydayis is only available as an extended-release formulation.[15] Adderall XR is approved to treat ADHD for up to 12 hours in individuals 6 years and older and uses a double-bead formulation. The capsule can be swallowed like a tablet, or it can be opened and the beads sprinkled over applesauce for comparable absorption. Upon ingestion, half of the beads provide immediate administration of medication, while the other half are enveloped in a coating which must dissolve, delaying absorption of its contents. It is designed to provide a therapeutic effect and plasma concentrations identical to taking two doses of Adderall IR four hours apart. Mydayis uses a longer-lasting triple-bead formulation and is approved to treat ADHD for up to 16 hours in individuals 13 years and older. In the United States, the immediate and extended-release formulations of Adderall are both available as generic drugs.[16] [17] Generic formulations of Mydayis became available in the US in October 2023.[18]

Enhancing performance

Adderall has been banned in the National Football League (NFL), Major League Baseball (MLB), National Basketball Association (NBA), and the National Collegiate Athletics Association (NCAA).[19] In leagues such as the NFL, there is a very rigorous process required to obtain an exemption to this rule even when the athlete has been medically prescribed the drug by their physician.

Recreational

See also: History and culture of substituted amphetamines.

Adderall has high potential for misuse as a recreational drug.[20] [21] [22] Adderall tablets can either be swallowed, crushed and snorted, or dissolved in water and injected.[23] Injection into the bloodstream can be dangerous because insoluble fillers within the tablets can block small blood vessels.

Many postsecondary students have reported using Adderall for study purposes in different parts of the developed world.[22] Among these students, some of the risk factors for misusing ADHD stimulants recreationally include: possessing deviant personality characteristics (i.e., exhibiting delinquent or deviant behavior), inadequate accommodation of disability, basing one's self-worth on external validation, low self-efficacy, earning poor grades, and having an untreated mental health disorder.[22]

Adverse effects

The adverse side effects of Adderall are many and varied, but the amount of substance consumed is the primary factor in determining the likelihood and severity of side effects. Adderall is currently approved for long-term therapeutic use by the USFDA. Recreational use of Adderall generally involves far larger doses and is therefore significantly more dangerous, involving a much greater risk of serious adverse drug effects than dosages used for therapeutic purposes.

Interactions

Pharmacology

Mechanism of action

Amphetamine, the active ingredient of Adderall, works primarily by increasing the activity of the neurotransmitters dopamine and norepinephrine in the brain.[27] It also triggers the release of several other hormones (e.g., epinephrine) and neurotransmitters (e.g., serotonin and histamine) as well as the synthesis of certain neuropeptides (e.g., cocaine and amphetamine regulated transcript (CART) peptides).[28] Both active ingredients of Adderall, dextroamphetamine and levoamphetamine, bind to the same biological targets, but their binding affinities (that is, potency) differ somewhat. Dextroamphetamine and levoamphetamine are both potent full agonists (activating compounds) of trace amine-associated receptor 1 (TAAR1) and interact with vesicular monoamine transporter 2 (VMAT2), with dextroamphetamine being the more potent agonist of TAAR1. Consequently, dextroamphetamine produces more stimulation than levoamphetamine;[29] [30] however, levoamphetamine has slightly greater cardiovascular and peripheral effects. It has been reported that certain children have a better clinical response to levoamphetamine.[31] [32]

In the absence of amphetamine, will normally move monoamines (e.g., dopamine, histamine, serotonin, norepinephrine, etc.) from the intracellular fluid of a monoamine neuron into its synaptic vesicles, which store neurotransmitters for later release (via exocytosis) into the synaptic cleft.[33] When amphetamine enters a neuron and interacts with VMAT2, the transporter reverses its direction of transport, thereby releasing stored monoamines inside synaptic vesicles back into the neuron's intracellular fluid. Meanwhile, when amphetamine activates, the receptor causes the neuron's cell membrane-bound monoamine transporters (i.e., the dopamine transporter, norepinephrine transporter, or serotonin transporter) to either stop transporting monoamines altogether (via transporter internalization) or transport monoamines out of the neuron; in other words, the reversed membrane transporter will push dopamine, norepinephrine, and serotonin out of the neuron's intracellular fluid and into the synaptic cleft. In summary, by interacting with both VMAT2 and TAAR1, amphetamine releases neurotransmitters from synaptic vesicles (the effect from VMAT2) into the intracellular fluid where they subsequently exit the neuron through the membrane-bound, reversed monoamine transporters (the effect from TAAR1).

Pharmacokinetics

Related endogenous compounds

History

See main article: History and culture of substituted amphetamines.

The pharmaceutical company Rexar reformulated their popular weight loss drug Obetrol following its mandatory withdrawal from the market in 1973 under the Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act due to the results of the Drug Efficacy Study Implementation (DESI) program (which indicated a lack of efficacy). The new formulation simply replaced the two methamphetamine components with dextroamphetamine and amphetamine components of the same weight (the other two original dextroamphetamine and amphetamine components were preserved), preserved the Obetrol branding, and despite it lacking FDA approval, it still made it onto the market and was marketed and sold by Rexar for many years.

In 1994, Richwood Pharmaceuticals acquired Rexar and began promoting Obetrol as a treatment for ADHD (and later narcolepsy as well), now marketed under the new brand name of Adderall, a contraction of the phrase "A.D.D. for All" intended to convey that "it was meant to be kind of an inclusive thing" for marketing purposes.[34] The FDA cited the company for numerous significant CGMP violations related to Obetrol discovered during routine inspections following the acquisition (including issuing a formal warning letter for the violations), then later issued a second formal warning letter to Richwood Pharmaceuticals specifically due to violations of "the new drug and misbranding provisions of the FD&C Act". Following extended discussions with Richwood Pharmaceuticals regarding the resolution of a large number of issues related to the company's numerous violations of FDA regulations, the FDA formally approved the first Obetrol labeling/sNDA revisions in 1996, including a name change to Adderall and a restoration of its status as an approved drug product.[35] [36] In 1997 Richwood Pharmaceuticals was acquired by Shire Pharmaceuticals in a $186 million transaction.

Richwood Pharmaceuticals, which later merged with Shire plc, introduced the current Adderall brand in 1996 as an instant-release tablet.[37] In 2006, Shire agreed to sell rights to the Adderall name for the instant-release form of the medication to Duramed Pharmaceuticals.[38] DuraMed Pharmaceuticals was acquired by Teva Pharmaceuticals in 2008 during their acquisition of Barr Pharmaceuticals, including Barr's Duramed division.[39]

The first generic version of Adderall IR was introduced to market in 2002. Later on, Barr and Shire reached a settlement agreement permitting Barr to offer a generic form of the extended-release drug beginning in April 2009.[40]

Commercial formulation

Chemically, Adderall is a mixture of four amphetamine salts; specifically, it is composed of equal parts (by mass) of amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine sulfate, and dextroamphetamine saccharate. This drug mixture has slightly stronger effects than racemic amphetamine due to the higher proportion of dextroamphetamine.[41] Adderall is produced as both an immediate-release (IR) and extended-release (XR) formulation.[14] [42], ten different companies produced generic Adderall IR, while Teva Pharmaceutical Industries, Actavis, and Barr Pharmaceuticals manufactured generic Adderall XR., Shire plc, the company that held the original patent for Adderall and Adderall XR, still manufactured brand name Adderall XR, but not Adderall IR.

Comparison to other formulations

Adderall is one of several formulations of pharmaceutical amphetamine, including singular or mixed enantiomers and as an enantiomer prodrug. The table below compares these medications (based on U.S.-approved forms):

Society and culture

Legal status

Shortages

In February 2023, news organizations began reporting on shortages of Adderall in the United States that have lasted for over five months.[53] [54] The Food and Drug Administration first reported the shortage in October 2022.[55] In May 2023, 7 months into the shortage, the Food and Drug Administration commissioner Robert Califf stated that "a number of generic drugs are in shortage at any given time because there's not enough profit". He points out that Adderall is a special case because it is a controlled substance and the amount available for prescription is controlled by the Drug Enforcement Administration. He also faults a "tremendous increase in prescribing" due to virtual prescribing and general overprescribing and overdiagnosing, adding that "if only the people that needed these drugs got them, there probably wouldn't be a [stimulant medication] shortage".[56] [57] Some Americans have been outsourcing the time-consuming task of calling nearby pharmacies to check their Adderall availability.[58]

The shortage has continued into 2024. Despite efforts to increase production and improve distribution, supply chain issues and increased demand have perpetuated the scarcity of the medication.[59] Patients and healthcare providers have expressed concerns about the impact on treatment plans for ADHD and narcolepsy, as many individuals rely on this medication for managing their symptoms.[60] The FDA continues to monitor the situation and is working with manufacturers to address the shortage.[61]

Notes

Image legend

External links

Notes and References

  1. Vitiello B . Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function . Child and Adolescent Psychiatric Clinics of North America . 17 . 2 . 459–74, xi . April 2008 . 18295156 . 2408826 . 10.1016/j.chc.2007.11.010 .
  2. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E . European guidelines on managing adverse effects of medication for ADHD . European Child & Adolescent Psychiatry . 20 . 1 . 17–37 . January 2011 . 21042924 . 3012210 . 10.1007/s00787-010-0140-6 . 1435-165X .
  3. Kociancic T, Reed MD, Findling RL . Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children . Expert Opinion on Drug Safety . 3 . 2 . 93–100 . March 2004 . 15006715 . 10.1517/14740338.3.2.93 . 31114829 . 1744-764X .
  4. Clemow DB, Walker DJ . The potential for misuse and abuse of medications in ADHD: a review . Postgraduate Medicine . 126 . 5 . 64–81 . September 2014 . 25295651 . 10.3810/pgm.2014.09.2801 . 207580823 . 1941-9260 .
  5. News: Sagonowsky E . Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit . Fierce Pharma . 28 August 2017 . Questex LLC . 2 May 2020 . 16 December 2019 . https://web.archive.org/web/20191216011722/https://www.fiercepharma.com/marketing/shire-launches-new-adhd-drug-mydayis-as-it-weighs-a-neuroscience-exit . live .
  6. Babiskin AH, Zhang X . Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation . Journal of Pharmaceutical Sciences . 104 . 9 . 3170–3182 . September 2015 . 25973928 . 10.1002/jps.24474 .
  7. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present--a pharmacological and clinical perspective . Journal of Psychopharmacology . 27 . 6 . 479–496 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532 .
  8. Joyce BM, Glaser PE, Gerhardt GA . Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers . Psychopharmacology . 191 . 3 . 669–677 . April 2007 . 17031708 . 10.1007/s00213-006-0550-9 . 20283057 .
  9. Web site: Pharmacology . Evekeo CII (amphetamine sulfate) HCP . Arbor Pharmaceuticals, LLC . 2 May 2020 . 21 September 2020 . https://web.archive.org/web/20200921152314/https://www.evekeo.com/hcp/evekeo-pharmacology . dead .
  10. Web site: Prescribing Information & Medication Guide . Zenzedi (dextroamphetamine sulfate, USP) . Arbor Pharmaceuticals LLC . 2 May 2020 . 11 November 2020 . https://web.archive.org/web/20201111223440/https://zenzedi.com/docs/PIandMedicationGuide.pdf . live .
  11. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  12. Web site: Dextroamphetamine; Dextroamphetamine Saccharate; Amphetamine; Amphetamine Aspartate - Drug Usage Statistics . ClinCalc . 14 January 2024.
  13. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present – a pharmacological and clinical perspective . Journal of Psychopharmacology. 27 . 6 . 479–496 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532 . The intravenous use of d-amphetamine and other stimulants still pose major safety risks to the individuals indulging in this practice. Some of this intravenous abuse is derived from the diversion of ampoules of d-amphetamine, which are still occasionally prescribed in the UK for the control of severe narcolepsy and other disorders of excessive sedation. ... For these reasons, observations of dependence and abuse of prescription d-amphetamine are rare in clinical practice, and this stimulant can even be prescribed to people with a history of drug abuse provided certain controls, such as daily pick-ups of prescriptions, are put in place (Jasinski and Krishnan, 2009b)..
  14. Web site: Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet . DailyMed . Teva Pharmaceuticals USA, Inc. . 8 November 2019 . 22 December 2019 . 2 October 2019 . https://web.archive.org/web/20191002150413/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81 . live.
  15. Web site: Mydayis medication guide. Mydayis.com. en. 6 February 2024. October 2023.
  16. Web site: Generic Adderall Availability. Drugs.com. en. 6 February 2020. 28 May 2020. https://web.archive.org/web/20200528223452/https://www.drugs.com/availability/generic-adderall.html. live.
  17. Web site: Generic Adderall XR Availability. Drugs.com. en. 6 February 2020. 6 February 2020. https://web.archive.org/web/20200206144135/https://www.drugs.com/availability/generic-adderall-xr.html. live.
  18. Web site: Mydayis® (mixed-salts of a single-entity amphetamine product) – First-time generic. OptumRx. en. 6 February 2023.
  19. Web site: Moore DL . Do pro sports leagues have an Adderall problem?. USA TODAY. 4 May 2014. 23 November 2014. https://web.archive.org/web/20141123131934/http://www.usatoday.com/story/sports/nfl/2012/11/27/adderall-in-pro-sports/1730431/ . live.
  20. Web site: Commonly Abused Prescription Drugs Chart . National Institute on Drug Abuse . 7 May 2012 . https://web.archive.org/web/20120501092302/http://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs/commonly-abused-prescription-drugs-chart . 1 May 2012 . dead .
  21. Web site: Stimulant ADHD Medications – Methylphenidate and Amphetamines . National Institute on Drug Abuse . 7 May 2012 . 2 May 2012 . https://web.archive.org/web/20120502072325/http://www.drugabuse.gov/publications/infofacts/stimulant-adhd-medications-methylphenidate-amphetamines . dead .
  22. Abelman DD . 6 October 2017. Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review. Harm Reduction Journal. 14. 1. 68. 10.1186/s12954-017-0194-6. 28985738. 5639593. 1477-7517 . free .
  23. Web site: National Institute on Drug Abuse. 2009. Stimulant ADHD Medications – Methylphenidate and Amphetamines. National Institute on Drug Abuse. 27 February 2013. https://web.archive.org/web/20130312110514/http://www.drugabuse.gov/publications/drugfacts/stimulant-adhd-medications-methylphenidate-amphetamines. 12 March 2013. dead.
  24. Web site: Adderall XR Prescribing Information . 8–10 . United States Food and Drug Administration . December 2013 . 30 December 2013 . 30 December 2013 . https://web.archive.org/web/20131230233702/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf . live .
  25. Web site: Mydayis Prescribing Information. United States Food and Drug Administration. Shire US Inc.. 8 August 2017. 1–21. June 2017. 9 June 2019. https://web.archive.org/web/20190609083453/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf. live.
  26. Scassellati C, Bonvicini C, Faraone SV, Gennarelli M . Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses . J. Am. Acad. Child Adolesc. Psychiatry . 51 . 10 . 1003–1019.e20 . October 2012 . 23021477 . 10.1016/j.jaac.2012.08.015 . Although we did not find a sufficient number of studies suitable for a meta-analysis of PEA and ADHD, three studies20,57,58 confirmed that urinary levels of PEA were significantly lower in patients with ADHD compared with controls. ... Administration of D-amphetamine and methylphenidate resulted in a markedly increased urinary excretion of PEA,20,60 suggesting that ADHD treatments normalize PEA levels. ... Similarly, urinary biogenic trace amine PEA levels could be a biomarker for the diagnosis of ADHD,20,57,58 for treatment efficacy,20,60 and associated with symptoms of inattentivenesss.59 ... With regard to zinc supplementation, a placebo controlled trial reported that doses up to 30 mg/day of zinc were safe for at least 8 weeks, but the clinical effect was equivocal except for the finding of a 37% reduction in amphetamine optimal dose with 30 mg per day of zinc.110.
  27. Book: Malenka RC, Nestler EJ, Hyman SE . Sydor A, Brown RY . Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . 2009 . McGraw-Hill Medical . New York, USA . 9780071481274 . 154–157 . 2nd . Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin.
  28. Web site: Amphetamine: Biomolecular Interactions and Pathways . PubChem Compound . National Center for Biotechnology Information . 13 October 2013 . 13 October 2013 . https://web.archive.org/web/20131013122604/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#x301 . live.
  29. Lewin AH, Miller GM, Gilmour B . Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class . Bioorg. Med. Chem. . December 2011 . 19 . 23 . 7044–7048 . 22037049 . 10.1016/j.bmc.2011.10.007 . 3236098.
  30. Smith RC, Davis JM . Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man . . 53 . 1 . 1–12 . June 1977 . 407607 . 10.1007/bf00426687 . 37967136.
  31. Book: Explorations in Child Psychiatry . Springer Science & Business Media . 11 November 2013 . 9781468421279 . Anthony E . 93–94 . 28 April 2015 . 21 May 2016 . https://web.archive.org/web/20160521053637/https://books.google.com/books?id=Ob7eBwAAQBAJ . live.
  32. Methyiphenidate vs. Amphetamine: Comparative review . 2000 . Arnold LE . 15901046 . Journal of Attention Disorders . 3 . 4 . 200–211 . 10.1177/108705470000300403.
  33. Eiden LE, Weihe E . VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse . Ann. N. Y. Acad. Sci. . 1216 . 1 . 86–98 . January 2011 . 21272013 . 10.1111/j.1749-6632.2010.05906.x . VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the trace amines TYR, PEA, and thyronamine (THYR) ... [Trace aminergic] neurons in mammalian CNS would be identifiable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC). . 4183197 . 2011NYASA1216...86E .
  34. News: The Selling of Attention Deficit Disorder. Schwarz A . 14 December 2013. The New York Times. 22 April 2017. 0362-4331. 1 March 2015. https://web.archive.org/web/20150301054334/http://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html. live.
  35. Web site: (Collection of internal FDA information pertaining to the topic of Obetrol/Adderall). www.accessdata.fda.gov. US Food and Drug Administration. 27 April 2017. 17 May 2017. https://web.archive.org/web/20170517033551/https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/11522S010_Adderall.pdf. live.
  36. News: REGULATORY NEWS: Richwood's Adderall. http://arquivo.pt/wayback/20160523200531/http://www.elsevierbi.com/Publications/Health-News-Daily/1996/2/22/REGULATORY-NEWS-Richwoods-Adderall. dead. 23 May 2016. 29 May 2013. Health News Daily. 22 February 1996.
  37. Web site: APPROVAL LETTER. United States Food and Drug Administration. 30 December 2013. 22 August 2013. https://web.archive.org/web/20130822033454/http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/11522S010_Adderall.pdf. live.
  38. Web site: August 2006 News Archives: Barr and Shire Sign Three Agreements . GenericsWeb . 30 December 2013 . WOODCLIFF LAKE, N.J., Aug. 14 /PRNewswire-FirstCall/ – Barr Pharmaceuticals, Inc. today announced that its subsidiary Duramed Pharmaceuticals, Inc. and Shire plc have signed a Product Acquisition Agreement for ADDERALL(R) (immediate-release mixed amphetamine salts) tablets and a Product Development Agreement for six proprietary products, and that its subsidiary Barr Laboratories, Inc. (Barr) has signed a Settlement and License Agreement relating to the resolution of two pending patent cases involving Shire's ADDERALL XR(R) ... . 8 February 2014 . https://web.archive.org/web/20140208010946/http://www.genericsweb.com/news/generics_industry_news_archive/August2006.html . dead .
  39. Web site: Teva Completes Acquisition of Barr . Drugs.com . 31 October 2011 . 8 March 2012 . https://web.archive.org/web/20120308020446/http://www.drugs.com/news/teva-completes-acquisition-barr-15356.html . live .
  40. News: Teva sells 1st generic of Adderall XL in US. 2 April 2009. 22 April 2009. Associated Press. Forbes Magazine. https://web.archive.org/web/20090409082544/http://www.forbes.com/feeds/ap/2009/04/02/ap6248888.html. 9 April 2009.
  41. Miller GM . The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity . J. Neurochem. . 116 . 2 . 164–76 . January 2011. 21073468 . 3005101 . 10.1111/j.1471-4159.2010.07109.x .
  42. Web site: Adderall XR Prescribing Information . Shire US Inc . United States Food and Drug Administration . December 2013 . 30 December 2013 . 30 December 2013 . https://web.archive.org/web/20131230233702/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf . live .
  43. Web site: Controlled Drugs and Substances Act (S.C. 1996, c. 19). 25 April 2017. 23 May 2013. 3 April 2011. https://web.archive.org/web/20110403004630/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/. live.
  44. Web site: Importing or Bringing Medication into Japan for Personal Use . Japan Ministry of Health, Labour and Welfare . 13 October 2013 . 13 July 2013 . https://web.archive.org/web/20130713064422/http://www.mhlw.go.jp/english/topics/import/ . live .
  45. Web site: Moving to Korea brings medical, social changes . P. . The Korean Times . 25 May 2012 . 8 February 2013 . 3 October 2014 . https://web.archive.org/web/20141003122116/http://www.koreatimes.co.kr/www/news/nation/2012/10/319_111757.html . live .
  46. Web site: Caught in the Dragnet. 2 August 2002. 18 November 2018. 19 November 2018. https://web.archive.org/web/20181119010732/http://www.taipeitimes.com/News/feat/archives/2002/08/11/0000159895/4. live.
  47. Web site: 吃「聰明藥」反而變笨？小孩能吃嗎？利他能副作用公開. 28 June 2023.
  48. Web site: Thailand Law . Government of Thailand . 23 May 2013 . dead . https://web.archive.org/web/20140308001155/http://narcotic.fda.moph.go.th/faq/upload/Thai%20Narcotic%20Act%202012.doc._37ef.pdf . 8 March 2014 .
  49. Web site: Class A, B and C drugs . Home Office, Government of the United Kingdom . 23 July 2007 . https://web.archive.org/web/20070804233232/http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/ . 4 August 2007 . dead .
  50. Web site: Trends in Methamphetamine/Amphetamine Admissions to Treatment: 1993–2003 . Substance Abuse and Mental Health Services Administration . United States Department of Health and Human Services . The Drug and Alcohol Services Information System (DASIS) Report . 6 May 2016 . dead . https://web.archive.org/web/20130305100340/http://www.oas.samhsa.gov/2k6/methTx/methTX.htm . 5 March 2013 .
  51. Book: United Nations Office on Drugs and Crime . Preventing Amphetamine-type Stimulant Use Among Young People: A Policy and Programming Guide . United Nations . New York . 2007 . 978-92-1-148223-2 . 7 February 2012 . 16 October 2013 . https://web.archive.org/web/20131016082310/http://www.unodc.org/pdf/youthnet/ATS.pdf . live .
  52. Web site: List of psychotropic substances under international control . International Narcotics Control Board . United Nations . Vienna . 19 November 2005 . https://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf . 5 December 2005 . dead .
  53. News: The ADHD medication shortage is getting worse. What went wrong?—Neither drugmakers nor the DEA anticipated a sharp rise in ADHD diagnoses during the pandemic. Now an entire class of medications may be in short supply. . 6 February 2023 . NBC . 25 February 2023.
  54. News: Adderall shortage raises questions about widespread dependency on the drug . 25 November 2022 . PBS Newshour . 25 February 2023.
  55. News: Hart B . Where's the Urgency on the Adderall Shortage? . 27 March 2023 . Intelligencer . 27 March 2023 . en-us.
  56. News: 'Exciting Time': FDA Commissioner Talks AI and Misinformation . 31 May 2023. WebMD.
  57. News: FDA Commissioner Blames Adderall Shortage on Stimulant Overuse, Telehealth, Generics . 2 June 2023. Anni Layne Rodgers via Additidemag.
  58. News: Maiberg . Emanuel . June 11, 2024 . Americans Are Hiring People in the Philippines to Help Them Find Adderall . June 11, 2024 . 404 Media.
  59. Web site: Adderall Shortage Persists in 2024. Pharma Manufacturing. 2024-06-01. 2024-07-12.
  60. News: Smith. Jane. Ongoing Adderall Shortage Affects Millions. Health News. 2024-05-15. 2024-07-12.
  61. Web site: FDA Update on Adderall Shortage. U.S. Food and Drug Administration. 2024-06-20. 2024-07-12.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Adderall".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.